Mangalam Drugs And Organics Ltd vs Novartis India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Mangalam Drugs and Organics Ltd is ₹ 30.38 as of 18 May 15:30 . The P/E Ratio of Mangalam Drugs and Organics Ltd is 0 as of March 2024 .The P/E Ratio of Novartis India Ltd is 0 as of March 2024 . The Market Cap of Mangalam Drugs and Organics Ltd is ₹ 146.65 crore as of March 2024 .The Market Cap of Novartis India Ltd is ₹ 0 crore as of March 2024 . The revenue of Mangalam Drugs and Organics Ltd for the Mar '26 is ₹ 67.38 crore as compare to the Dec '25 revenue of ₹ 58.6 crore. This represent the growth of 14.98% The revenue of Novartis India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Mangalam Drugs and Organics Ltd for the Mar '26 is ₹ -5.53 crore as compare to the Dec '25 ebitda of ₹ -1.32 crore. This represent the growth of 318.94% The ebitda of Novartis India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Mangalam Drugs and Organics Ltd changed from ₹ 2.68 crore to ₹ -13.42 crore over 8 quarters. This represents a CAGR of NaN% The net profit of Novartis India Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Mangalam Drugs and Organics Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 years .

About Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Limited was initially incorporated as 'Advent Pharma Private Limited' on April 18, 1972.
On July 1, 1997, the Company changed the name from Advent Pharma Private Limited to Mangalam Drugs and Organics Private Limited.
Thereafter, it converted the status into a Public Limited Company, changing the name to Mangalam Drugs and Organics Limited on August 10, 2001.
The company was established to set up a plant for manufacture of organic and inorganic chemicals. The company is engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates.
The company has their manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra.

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

FAQs for the comparison of Mangalam Drugs and Organics Ltd and Novartis India Ltd

Which company has a larger market capitalization, Mangalam Drugs and Organics Ltd or Novartis India Ltd?

Market cap of Mangalam Drugs and Organics Ltd is 48 Cr while Market cap of Novartis India Ltd is 2,914 Cr

What are the key factors driving the stock performance of Mangalam Drugs and Organics Ltd and Novartis India Ltd?

The stock performance of Mangalam Drugs and Organics Ltd and Novartis India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mangalam Drugs and Organics Ltd and Novartis India Ltd?

As of May 18, 2026, the Mangalam Drugs and Organics Ltd stock price is INR ₹30.38. On the other hand, Novartis India Ltd stock price is INR ₹1180.5.

How do dividend payouts of Mangalam Drugs and Organics Ltd and Novartis India Ltd compare?

To compare the dividend payouts of Mangalam Drugs and Organics Ltd and Novartis India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.